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Background: Noni fruit is widely consumed in tropical regions of Indonesia to the Hawaiian Islands. The noni plant
has a long history of use as a medicinal plant to treat a wide variety of ailments including CNS disorders. The
present investigation was designed to evaluate the antipsychotic effect of noni fruits (Morinda citrifolia Linn.) using
mouse models of apomorphine-induced climbing behaviour and methamphetamine-induced stereotypy (licking,
biting, gnawing and sniffing).
Methods: In acute study, the methanolic extract of Morinda citrifolia (MMC) at different doses 1, 3, 5, 10 g/kg was
administered orally one hour prior to apomorphine (5 mg/kg, i.p) and methamphetamine ( 5 mg/kg, i.p) injection
respectively in Swiss albino mice. In chronic studies, (TAHITIAN NONIW Juice, TNJ) was made available freely in daily
drinking water at 30, 50 and 100% v/v for 7 days; 30 and 50% v/v for 21 days respectively. On the test day, an
equivalent average daily divided dose of TNJ was administered by oral gavage one hour prior to apomorphine
treatment. Immediately after apomorphine/ methamphetamine administration, the animals were placed in the
cylindrical metal cages and observed for climbing behaviour/ stereotypy and climbing time.
Results: The acute treatment of MMC (1, 3, 5, 10 g/kg, p.o) significantly decreased the apomorphine-induced cage
climbing behaviour and climbing time in mice in a dose dependent manner. The MMC also significantly inhibited
methamphetamine-induced stereotypy behaviour and climbing time in mice dose-dependently. The 7 and 21 days
treatment of TNJ in drinking water at 50 and 100%v/v significantly alleviated the apomorphine-induced climbing
behaviour and climbing time in mice.
Conclusions: The present study results demonstrated the antidopaminergic effect of Morinda citrifolia Linn. in mice,
suggesting that noni has antipsychotic-like activity which can be utilized in the treatment of psychiatric disorders.
However further studies are warranted to identify the active principles responsible for the antipsychotic activity of noni.
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Psychosis is a chronic recurrent neuropsychiatric dis-
order that alters the quality of life of the sufferers and it
has been a major public health concern [1]. Current
drug treatments are limited by poor efficacy and toler-
ability. Since psychiatric disorders are on the rise, clini-
cians are looking for alternative remedies and herbal
medications for the treatment of neurobehavioral disor-
ders. Noni is the general name given for the species
Morinda citrifolia Linn (Rubiaceae) and is also known in
different communities as Indian Mulberry, nunaakai (in* Correspondence: pandiphd@gmail.com
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reproduction in any medium, provided the orTamil), dog dumpling (Barbados), mengkudu (Indonesia
and Malaysia), apatot (Philippines), kumudu (Bali), pace
(Java), beach mulberry, cheese fruit or noni (Hawaii).
Noni is an evergreen tree found growing in open coastal
regions at sea level and in forest areas up to about 1300
feet above sea level. Noni is identifiable by its straight
trunk, large, bright green and elliptical leaves, white
tubular flowers and its distinctive, ovoid, “grenade-like”
yellow fruit. The fruit can grow in size up to 12 cm or
more and has a lumpy surface covered by polygonal-
shaped sections. The seeds, which are triangular shaped
and reddish brown, have an air sac attached at one end,
which makes the seeds buoyant. The mature noni fruit
has a foul taste and odour [2]. Noni juice has been usedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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2,000 years to aid a wide range of health illness. The
fruit juice is in high demand as alternative medicine for
different kinds of ailments such as arthritis, diabetes,
high blood pressure, muscle aches and pains, menstrual
difficulties, headaches, heart disease, AIDS, cancers, gas-
tric ulcers, sprains, mental depression, senility, poor di-
gestion, atherosclerosis, blood vessel problems, and drug
addiction [3,4]. A wide variety of pharmacological activ-
ities have been reported for fruit, leaf and root extracts
of noni such as analgesic [5], anti-inflammatory [6], anti-
oxidant [7,8], immunomodulatory [9], anti-tumor [10],
hepatoprotective [11], blood pressure lowering and vaso-
dilatory [12,13], cardio protective [14], antifungal [15],
phytoestrogenic [16], wound healing [17], insulino-
trophic [18] and anti-osteoporotic activity [19]. Never-
theless, there have been only a few reports on the use of
noni for CNS disorders such as anxiolytic and sedative
[20], nootropic [21], antiepileptic [22], neuroprotective
effect against stress-induced cognitive impairment [23]
and some neuropharmacological effects [24].
Morinda citrifolia is regarded as a safe antiemetic drug
in primary health care in Thailand [25]. The decoction
or infusion of roasted mature unripe noni fruits is
recommended to relieve the symptoms of mild nausea
and vomiting [26]. The prokinetic and antiemetic actions
of noni fruit extract were detected by Chuthaputti et al.
[27] in which they found that the intestinal transit was
delayed by apomorphine (a potent agonist of dopamine
D2 receptor) in mice meanwhile emesis induced by apo-
morphine was reduced in dogs. The results indicated
that an aqueous extract of noni fruit at the dose equiva-
lent to crude drug 10–20 g/kg body weight and also at
the dose equivalent to crude drug 40 g/kg body weight,
might contain a weak antidopaminergic agent respon-
sible for its prokinetic in mice and an antiemetic effect
observed in humans respectively [25]. Conversely, it was
reported that the administration of Morinda citrifolia
fruit extract significantly increased the brain levels of
monoamines including dopamine in rats [22]. These
contradictory results led us to conduct further studies of
noni on the dopaminergic system. Hence the present
study is designed to evaluate the neuromodulatory effect
of noni (Morinda citrifolia Linn) on the dopaminergic
system using firstly, mouse model of apomorphine-
induced climbing behaviour and climbing time and sec-
ondly, methamphetamine-induced stereotypy (licking,
biting, gnawing and sniffing) and climbing time.
Methods
Plant material
Fresh unripe fruits (dark green) of M. citrifolia were col-
lected on January 2012 from Malacca, Malaysia. The
plant material was taxonomically identified andauthenticated by Rimba Ilmu, Institute of Biological
Sciences, University of Malaya and the voucher speci-
men (KLU 47738) was deposited at Rimba Ilmu for fu-
ture reference. The fruits were cut into thin slices and
shade dried. The shade dried fruit slices were pulverized
in a mechanical grinder to obtain a coarse powder.
Preparation of Morinda citrifolia fruit extract
The methanolic extract of Morinda citrifolia (MMC)
was prepared using cold extraction with sonication. The
coarse fruit powder (1.8 kg) was soaked with 10 L of
methanol (Scharlau, Spain, isocratic HPLC grade) for 20
h followed by sonication using a water bath sonicator at
30°C for another 4 h. The resultant solution was evapo-
rated under vacuum in a rotary evaporator to obtain a
dry mass extract (yield: 14.36% w/w). The dried solvent
free crude MMC was stored in 4°C in an airtight, la-
belled, amber-colored container until further use.
Animals
Swiss albino male mice (25-30 g), obtained from the la-
boratory animal centre, University of Malaya were used
in this study. The mice were housed in polycarbonate
cages in a group of six to seven animals under standard
laboratory conditions at temperature of 22±1°C and 12 h
light: 12 h dark cycle. Animals were fed with standard
laboratory food pellet and water ad libitum. The animals
were acclimatized to the experimental room and handled
for one week prior to start of the experimentation.
Animal Care and Use Committee, Faculty of Medicine,
University of Malaya, Kuala Lumpur approved the ex-
perimental protocol (ACUC Ethics No. FAR/27/01/
2012/PV (R)) and care of the animals were taken as
per guidelines of the Council for International
Organization of Medical Sciences (CIOMS) on animal
experimentation [28].
Drugs and chemicals
Apomorphine hydrochloride and sodium metabisulphite
(Sigma-Aldrich, USA), haloperidol (Manace InjectionW,
Duopharma (M) SDN BHD, Malaysia) and metham-
phetamine hydrochloride (MOSTI, Malaysia) were used.
All the drug solutions were prepared fresh in normal sa-
line and administered intraperitoneally (i.p) in a constant
volume of 1 ml/100 g body weight of the animal. Apo-
morphine hydrochloride was dissolved in saline contain-
ing sodium metabisulphite (0.125% w/v). The MMC was
suspended in 1% w/v sodium carboxy methyl cellulose
(CMC) solution and administered orally (p.o). CMC so-
lution was served as vehicle control (VEH). Commercial
noni fruit juice, TNJ was obtained from Morinda Inter-
national Inc, Malaysia. TNJ is a fruit mixture of 89%
noni fruit puree and 11% of grape and blueberry juice
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noni juice is unpalatable.Statistical analysis
The data are expressed as mean ± S.E.M. The statistical
significance of differences between groups were evalu-
ated by one way analysis of variance (ANOVA) followed
by the student's t-test. Stereotypy and climbing behav-
iour was analysed by Kruskal-Wallis test followed by
Mann–Whitney U-test because nonparametric statistics
are needed with all or none or rating scale scores. All
data analyses were conducted using GraphPad Prism 5
statistical software. A level of p < 0.05 was considered
statistically significant.Experimental design
Apomorphine-induced climbing behaviour in mice
Administration of apomorphine to mice results in a pe-
culiar climbing behaviour characterized initially by rear-
ing and then spontaneous climbing activity [29]. A
cylindrical metal cage (18×19 cm) consisting of vertical
(1 cm apart) and horizontal (4.5 cm apart) metal bars
(2 mm) with upper lid was used in the present study. In
acute studies, test groups received different doses of
MMC (1, 3, 5 and 10 g/kg, p.o), and the vehicle-treated
group received 1% w/v CMC solution (1 ml/100 g, p.o),
one hour before apomorphine injection (5 mg/kg, i.p).
The reference drug, haloperidol (dopamine D2 receptor
antagonist) treated positive control group received a
dose (2 mg/kg, i.p) 30 min before apomorphine injec-
tion. In chronic studies, TNJ was made available freely
in the daily drinking water at 30, 50 and 100% v/v for 7
days; 30 and 50% v/v for 21 days respectively in different
sets of animals. The mean daily dose of noni juice based
on daily intake of water was calculated and found to be
~6, 10 and 13 ml/100 g/d for 30, 50 and 100% v/v re-
spectively. On the test day, an equivalent average daily
divided dose of TNJ was administered by oral gavage
one hour prior to apomorphine treatment. Initially, naïve
mice were placed individually at the base of the cage for
15 min to explore freely. Immediately after apomorphine
administration, the animals were placed back into the
corresponding metal cages and observed for climbing
behaviour. An observer who was blind to drug treatment
measured the total time spent on the wall of the cage
whereby the climbing behaviour of individual mice was
scored at 5-min intervals for a period of 30 min. The
scoring system used as follows: 0 = four paws on the
floor, 2 = two paws on the wall of the cage, 4 = four
paws on the wall of the cage (climbing) and the score
corresponding to the posture the animal adopted the
longest were recorded. Climbing scores across each
5 min interval for a period of 30 min were thensummarized and expressed as climbing index, thus pro-
viding a maximum possible climbing index of 24.
Methamphetamine-induced stereotypy and climbing time in
mice
The apparatus and procedures that were used are the
same as described elsewhere [30] with some modifica-
tions. They were randomly assigned to each drug regi-
men and received the MMC (1, 3 and 5 g/kg, p.o) one
hour before methamphetamine (5 mg/kg, i.p) injection.
The positive control group received haloperidol (2 mg/kg,
i.p) 30 min before methamphetamine injection. Naïve mice
were initially placed individually in cylindrical metal cages
described in the previous experiment for 15 min to
acclimatize to the new environment. Immediately after
methamphetamine administration, the mice were placed
inside the cage at its base. After 30 min of methampheta-
mine administration, the animal was placed on the inner
lid of the cage and lid was closed. Methamphetamine does
not induce spontaneous climbing behaviour as apomorph-
ine does and hence when the methamphetamine treated
animal is placed on the lid of the cage, it remained on it
for a longer time while the saline treated animal will imme-
diately go down to the base. The total time spent on the
inner lid/ wall of the cage was measured for 30 min. The
intensity of stereotyped behaviour of individual mice was
scored at 15-min intervals for a period of 60 min. The scor-
ing system used was: Score 0 (no change compared to con-
trol), 1 (discontinuous sniffing, constant exploratory
activity), 2 (continuous sniffing, periodic exploratory activ-
ity), 3 (continuous sniffing, discontinuous biting, gnaw-
ing or licking), and 4 (continuous biting, gnawing or
licking; no exploratory activity).
Safety study
Animals were divided in groups of six each. The acute
oral toxicity study was performed in test groups that
were treated with either MMC (20 g/kg), or TNJ (20 ml/
100 g, 4 divided doses in 30 min interval). The max-
imum volumes of administration in mice used to be
5 ml/100g. Vehicle treated group received 1%w/v CMC
(1 ml/100 g, p.o) served as the control. The mice were
allowed food and water ad libitum during the 24 h test
period and kept under regular observation of gross
physiological, behavioural changes (skin state, salivation,
whimpering, trembling, locomotion and excretion) and
mortality. Body weight of each mouse was recorded daily
[5,13].
Results
Apomorphine-induced climbing behaviour in mice
Pre-treatment with the MMC (1, 3, 5 and 10 g/kg, p.o)
significantly (p< 0.01) inhibited apomorphine-induced
climbing behaviour (Figure 1a and b). Similarly, MMC
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Figure 1 Effect of MMC, (g/kg, p.o) on cage climbing behaviour
and climbing time induced by apomorphine in mice. (a) Each
point represents the mean ± SEM from the scores obtained from six
animals. (b) The cumulative scores were measured for 30 min after
administration of apomorphine. (c) Total time spent on the wall of
the cage. ### p < 0.001, ## p < 0.01 compared with that of the
saline group; * p< 0.05, ** p < 0.01, ***p <0.001 compared with that
of the apomorphine (APO, mg/kg, i.p) group. Haloperidol (2 mg/kg,
i.p) showed 100% inhibition of apomorphine response (data not
shown). n.s- not significant.
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Figure 2 Effect of TNJ, (% v/v, 7 days in the drinking water) on
cage climbing behaviour and climbing time induced by
apomorphine in mice. (a) Each point represents the mean ± SEM
from the scores obtained from seven animals. (b) The cumulative
scores were measured for 30 min after administration of apomorphine.
(c) Total time spent on the wall of the cage. ### p < 0.001, ## p < 0.01
compared with that of the saline group; * p< 0.05, ** p < 0.01, ***
p <0.001 compared with that of the apomorphine (APO, mg/kg, i.p)
group. n.s- not significant.
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P <0.01] reduced the total time spent on the wall of the
cage in apomorphine-induced mice dose-dependently
(Figure 1c). MMC (1- 10 g/kg, p.o) per se did not pro-
duce either climbing behaviour or ataxia in this experi-
ment, when compared to the vehicle control group (data
not shown).
The 7 days pre-treatment with TNJ in drinking
water at 30, 50 and 100 %v/v significantly (p< 0.01)
alleviated apomorphine-induced climbing behaviour(Figure 2a and b). TNJ also significantly [F (4, 30) = 12.88;
P <0.01] declined the total time spent on the wall of the
cage in apomorphine-induced mice dose-dependently
(Figure 2c).
Pre-treatment with TNJ (30 and 50%v/v) for 21 days
also significantly [F (3, 20) = 33.36; P <0.01] reduced
climbing behaviour and total time spent on the wall of
the cage in apomorphine-induced mice (Figure 3a,b
and c). Haloperidol (2 mg/kg, i.p) completely reversed
the apomorphine-induced climbing behaviour and
climbing time in mice (data not shown).
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Figure 3 Effect of TNJ, (% v/v, 21 days in the drinking water)
on cage climbing behaviour and climbing time induced by
apomorphine in mice. (a) Each point represents the mean ± SEM
from the scores obtained from six animals. (b) The cumulative scores
were measured for 30 min after administration of apomorphine. (c)
Total time spent on the wall of the cage. ### p < 0.001, ## p < 0.01
compared with that of the saline group; * p< 0.05, ** p < 0.01,
***p <0.001 compared with that of the apomorphine (APO, mg/kg,
i.p) group . n.s- not significant.
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Figure 4 Effect of MMC, (g/kg, p.o) on stereotypies and
climbing time induced by methamphetamine in mice. (a) Each
point represents the mean ± SEM from the stereotypy scores obtained
from six animals. (b) The cumulative stereotypy scores were measured
during 30 to 60 min after administration of methamphetamine. (c)
Total time spent on the wall of the cage. ### p < 0.001, ## p < 0.01
compared with that of the saline group; *p< 0.05, ** p < 0.01,
***p <0.001 compared with that of the methamphetamine (METH,
mg/kg, i.p) group. Haloperidol (2 mg/kg, i.p) showed 100% inhibition
on methamphetamine-induced stereotypies in mice (data not shown).
n.s- not significant.
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in mice
Pre-treatment with MMC (1, 3, 5 g/kg, p.o) significantly
(p<0.0001) inhibited methamphetamine-induced stereo-
typy behaviour in a dose-dependent manner (Figure 4a
and b). It also significantly [F (4, 25) = 7.535; P < 0.01]
attenuated methamphetamine-induced climbing time in
mice (Figure 4c). Haloperidol (2 mg/kg, i.p) completely
reversed the methamphetamine-induced stereotypy and
climbing time in mice (data not shown).Safety study
The acute oral treatment with MMC at 20 g/kg and TNJ
at 20 ml/100 g did not produce any mortality or changes
in gross behaviour, as compared to vehicle treated group
when observed for 14 days.
Discussion
The behavioural responses observed in animals after ad-
ministration of the dopamine agonist, apomorphine are
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Mesolimbic and nigrostriatal dopaminergic pathways play
key roles in the mediation of locomotor activity and
stereotyped behaviour. Stereotyped behaviour is more
closely associated with the caudate striatum area of the
brain [31-33]. Animal models used for screening
antipsychotic drugs are based on the neurochemical hy-
pothesis of schizophrenia, involving mainly the neuro-
transmitters dopamine and glutamate [34]. Antagonism
of dopamine D2 receptors may be a common feature of
most clinically effective antipsychotic drugs, especially
those active against hallucinations and delusions [35].
The dopamine-based models usually employ apomorph-
ine, a direct agonist, or amphetamine, a drug that
increases the release of this neurotransmitter and blocks
its re-uptake. In the present study, acute pre-treatment
of MMC, (1-10 g/kg, p.o) in mice showed a significant
dose-dependent decrease in climbing behaviour and
climbing time induced by apomorphine. In addition, 7
and 21 days pre-treatment with TNJ (30, 50 and 100%
v/v in daily drinking water) also significantly alleviated
apomorphine-induced climbing behaviour and climbing
time in mice. The reference drug, haloperidol (2 mg/kg,
i.p) completely reversed the apomorphine-induced climb-
ing behaviour and climbing time in mice. Margarita et
al [24] demonstrated neuroleptic activity of the juice of
the ripe fruit of the noni in mice. Noni juice at different
doses (5, 10 and 100 ml/kg, i.p) equivalent to dried juice
powder doses (450, 900 and 1800 mg/kg, i.p) signifi-
cantly reduced stereotypies induced by amphetamine
(3 mg/kg, s.c) in a dose-dependent manner [24]. The
present study results are consistent with these findings
and revealed MMC and TNJ might have dopamine D1
and/or D2 receptors antagonistic phytoconstituents.
To further confirm these findings, another set of ex-
periment was carried out by replacing apomorphine with
methamphetamine. Methamphetamine is a member of
the family of phenethylamine. Methamphetamine causes
the norepinephrine, dopamine, and serotonin (5HT)
transporters to reverse their direction of flow. This in-
version leads to a release of these transmitters from the
vesicles to the cytoplasm and from the cytoplasm to the
synapse, causing increased stimulation of post-synaptic
receptors. Methamphetamine also indirectly prevents
the reuptake of these neurotransmitters, causing them to
remain in the synaptic cleft for a prolonged period [36].
It would then produce an effect that is similar to the
apomorphine-induced behaviour in mice which in this
case is stereotypy. Stereotyped licking, biting, and other
orofacial behaviours are known to involve nigrostriatal
dopaminergic neurotransmission [37] in distinct striatal
sub regions [38-40]. Importantly, it appears that control
of sniffing and biting is mediated by different striatal
sub regions [38]. Overall, mesolimbic dopaminergicmechanisms have been proposed to play a critical role
in the expression of stereotypy after acute psychosti-
mulant administration [41]. Since some of the specific
behaviours produced in these models closely resemble
that of humans abusing amphetamines, animals that
display stereotypy have been considered as an animal
model for amphetamine psychosis and are considered
to be particularly relevant to schizophrenia [42]. How-
ever, because of the compulsive and the repetitive na-
ture of the behaviour, amphetamine-induced stereotypy
have also been considered as potential animal models
of obsessive–compulsive disorder [43] and autism [44].
Methamphetamine-induced stereotypy persists for sev-
eral hours in rodents, and this abnormal behaviour
can be reversed by dopamine antagonists [45], but less
so by other agents [46]. The acute pre-treatment of
MMC (1, 3 and 5 g/kg, p.o) significantly decreased the
methamphetamine-induced stereotypy and cage climb-
ing time in a dose-dependent manner. These results
further confirm the antidopaminergic effect of MMC
of noni unripe fruits.
Analgesic properties for commercial noni juice in rats
have been reported in the literature. The results showed
that rats fed with 10% and 20% noni juice had greater
pain tolerance (162% and 212%, respectively) compared
with the placebo group [3]. Noni root extract (1600 mg/kg)
showed significant analgesic activity in mice through the
writhing and hotplate tests, similar to the effect of mor-
phine (75% and 81% protection using noni extract and
morphine, respectively), and it was also proven to be non-
toxic [5,47]. These studies suggested that the central
pharmacological effects of noni can be observed at higher
doses [24]. In the present study, the antidopaminergic
effects of MMC and TNJ were observed only at higher
doses.
Several oral toxicity studies in Sprague-Dawley rats,
using the widely consumed commercial noni fruit juice,
TNJ have been assessed [3,48]. Acute and sub chronic
(13 wks.) oral toxicity studies revealed no diverse effects
from consuming doses equivalent to 80 ml/kg body
weight/d [48]. Pureed noni fruit from Tahiti was admi-
nistered by oral gavage at a dose of 15 g/kg to Sprague-
Dawley rats. All animals survived and showed no signs
of toxicity or behavioural changes when observed for
two weeks. Conversely, all animals appeared healthy and
gained weight. Gross necropsies of all animals at the end
of 2 weeks revealed no pathological effects. Conse-
quently, the LD50 of noni fruit was found to be greater
than 15 g/kg [49]. Compounds are considered nontoxic
if the acute oral LD50 is greater than 5 g/kg, or if the
acute intraperitoneal LD50 is greater than 2 g/kg. The
LD50 of noni fruit juice and its crude extract are greater
than the minimum criteria for nontoxic status [48]. The
present acute toxicity results are consistent with these
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of TNJ at 200 ml/kg and MMC at 20 g/kg respectively
did not show any toxic effects and behavioural changes
when observed for 14 days.
It has been demonstrated that M. citrifolia possess
antiemetic property in patients who are considered high
risk for postoperative nausea and vomiting (PONV) after
various types of surgery. The 600 mg dose of noni ex-
tract (equivalent to 20 g of dried noni fruit/ 8.712 mcg
of scopoletin) was the minimum dose that effectively
reduced the incidence of postoperative nausea in the
early postoperative period [50]. However, this study
could not reveal the possible mechanism of action of M.
citrifolia for antiemetic action. Our study result suggests
that the antiemetic activity of M. citrifolia might be
mediated through dopaminergic pathways. It is well
known that dopamine D2 receptors in the area postrema
play an important role in the regulation of emetic
responses in ferrets, dogs and humans [51,52]. From a
clinical point of view, dopamine receptor antagonists
such as phenothiazines, butyrophenones and benza-
mides, which have affinity for dopamine D2 and D3
receptors, are used as antiemetic agents [53]. The contri-
butions of dopaminergic abnormalities to the patho-
physiology of schizophrenia have been studied most
intensively. The focus on dopaminergic abnormalities in
schizophrenia was prompted by the complementary
observations in humans that psychosis can be elicited by
psychostimulant medications such as d-amphetamine,
especially when they are abused, whereas the ability to
inhibit competitively the binding of dopamine to the D2
type of dopamine receptor is a pharmacological property
shared by all of the conventional antipsychotic medica-
tions [54]. The obtained antidopaminergic activity of M.
citrifolia in the present studies could be utilized in the
treatment of schizophrenia.
Conversely, it has been demonstrated that ethyl acetate
fraction of crude methanol extract of Morinda citrifolia at
a daily dose of 200 and 400 mg/kg when administered to
rats for 15 days significantly increased the brain levels of
serotonin, dopamine and noradrenaline, which could be
attributed to the significant protection offered against
MES induced seizures in rats [22]. These opposing effects
could be due to dose differences. This kind of biphasic re-
sponse was extensively studied and reported in the litera-
ture [55]. However, further neurochemical studies in the
brain are necessary to confirm this hypothesis and such
studies are indeed underway in our laboratory.
Phytochemical studies using high performance liquid
chromatographic (HPLC) fingerprint profile of the
MeOH extracts of noni fruit revealed three major peaks
representing scopoletin, rutin and quercetin (retention
times: 25.72, 28.57 and 32.70 min, respectively), together
with several minor peaks. These are major bioactiveconstituents of noni responsible for various pharmaco-
logical activities [20,56]. The antipsychotic like-effect of
MMC and TNJ observed in the present study might be
attributed to the presence of these phytoconstituents. In-
vestigation of antidopaminergic active phytoconstituents
responsible for noni's antipsychotic effect by using
bioassay-guided chromatographic fractionation is cur-
rently underway in our laboratory.
Conclusions
In conclusion, this study provides evidence that MMC
dose-dependently attenuated the stereotyped behaviour
induced by apomorphine and methamphetamine re-
spectively in Swiss albino mice. In addition, the com-
mercial noni juice TNJ when administered in drinking
water for 7 and 21 days respectively also alleviated
apomorphine-induced stereotypy in mice. These observed
effects might be attributed to dopaminergic antagonistic
and/or the reduction of dopamine availability in the brain.
The antidopaminergic activity of noni fruits might be re-
sponsible for the traditional claim of effective treatment of
nausea and vomiting. However, further studies are war-
ranted to isolate and characterize these compounds for
the effective utilization in the treatment of various kinds
of emesis and psychiatric disorders.
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